NASDAQ: NBTXNanobiotix Sa Stock
$4.86-0.05 (-1.02%)
Updated Oct 15, 2024
NBTX Price
$4.86
Fair Value Price
N/A
Market Cap
$230.49M
52 Week Low
$4.14
52 Week High
$8.96
P/E
-5.98x
P/B
-9.63x
P/S
5.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$46.38M
Earnings
-$35.99M
Gross Margin
100%
Operating Margin
-48.55%
Profit Margin
-79.3%
Debt to Equity
-4.98
Operating Cash Flow
-$1M
Beta
1.07
Next Earnings
Nov 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NBTX Overview
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NBTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NBTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NBTX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
NBTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NBTX due diligence checks available for Premium users.
Be the first to know about important NBTX news, forecast changes, insider trades & much more!
NBTX News
Valuation
NBTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.98x
Industry
-141.41x
Market
26.94x
NBTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-9.63x
Industry
6.09x
NBTX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
NBTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NBTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$93.2M
Liabilities
$116.6M
Debt to equity
-4.98
NBTX's short-term assets ($88.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NBTX's short-term assets ($88.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NBTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NBTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NBTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NBTX vs Biotech Stocks
Nanobiotix Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.